Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stilbestrol plus immune-targeted chemotherapy in peritoneal metastatic carcinoma refractory to conventional treatment
ChiCTR2400083649Phase 2Recruiting
- Sponsor
- Centre for Gastroenterology, The Seventh Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of diethylstilbestrol in primary peritoneal cancer (PPC), gastric cancer (GC), colorectal cancer (CRC) and 2 more, sponsored by Centre for Gastroenterology, The Seventh Affiliated Hospital of Sun Yat-sen University. Primary endpoint: ORR rate for 6 cycles. Started Apr 2024; status: recruiting.
02
Drugs
diethylstilbestrol
03
Conditions
primary peritoneal cancer (PPC)gastric cancer (GC)colorectal cancer (CRC)ovarian cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2400083649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083649.